Back to Search Start Over

FibroGen fails again in DMD, continuing rotten run of phase 3 flops.

Authors :
Taylor, Nick Paul
Source :
FierceBiotech; 8/30/2023, pN.PAG-N.PAG, 1p
Publication Year :
2023

Abstract

Pamrevlumab flunked a second phase 3 Duchenne muscular dystrophy trial in quick succession to send FibroGen deeper into the mire. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
DUCHENNE muscular dystrophy

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
171346437

Tools

Authors Abstract Subjects Details